People channel feed

GSK déjà vu: Time for a top-down switch as new CEO tries to con­quer old R&D demons

8 years ago
R&D

Ju­ry finds Mar­tin Shkre­li guilty on 3 counts of se­cu­ri­ties fraud — and he's 'de­light­ed'

8 years ago

Aeter­na Zen­taris claims it boot­ed CEO and then dis­cov­ered a plot to grab con­trol of its lead as­set

8 years ago

Top FDA of­fi­cial ac­cused CDER chief Wood­cock of ap­pear­ing bi­ased, brow­beat­ing re­view­ers in de­mand­ing eteplirsen OK

8 years ago
Pharma

Top No­var­tis man­u­fac­tur­ing ex­ec jumps ship, takes charge of in­dus­tri­al­iz­ing Mod­er­na’s mR­NA tech

8 years ago

Af­ter tak­ing a PhI­II thrash­ing, As­traZeneca comes out swing­ing with break­through ti­tles, new can­cer hires

8 years ago

The glob­al ri­val­ry for top sci­en­tif­ic tal­ent in bio­phar­ma R&D is about to get a lot hot­ter

8 years ago
R&D
Pharma

Mis­sion pos­si­ble: As­traZeneca CEO So­ri­ot ral­lies the troops, promis­ing to fight on

8 years ago

Lat­est tes­ti­mo­ny in Shkre­li tri­al cen­ters on a Retrophin stock deal gone sour

8 years ago

Pas­cal So­ri­ot is stay­ing at As­traZeneca af­ter all, con­firm­ing up­com­ing pre­sen­ta­tion - re­ports

8 years ago

Glax­o­SmithK­line woos Pfiz­er med­i­c­i­nal sci­ences chief Tony Wood to high-lev­el R&D job

8 years ago

Ex-GSK CEO An­drew Wit­ty goes biotech, tak­ing a board seat at G1

8 years ago

Ter­ri­ble op­tics: As­traZeneca shares take a hit fol­low­ing re­port that CEO So­ri­ot is mov­ing to Te­va

8 years ago

Cel­gene vet Jack­ie Fouse grabs the reins of a Vivek Ra­maswamy vant-up

8 years ago
Startups

Fed­s' case spot­lights Shkre­li’s dis­as­trous biotech short -- which forced him to launch Retrophin

8 years ago

Court pa­pers out­line an an­gry show­down be­tween Pas­cal So­ri­ot and a de­part­ing Luke Miels

8 years ago

A judge or­ders Mar­tin Shkre­li to zip it -- af­ter Twit­ter shuts down his lat­est on­line ac­count

8 years ago

Shire’s Orn­skov dic­tates an­oth­er big re­vamp, with R&D/HQ mov­ing in­to Cam­bridge

8 years ago
Pharma

Ge­nius or chron­ic liar? The Mar­tin Shkre­li fraud tri­al gets un­der­way with two rad­i­cal­ly op­posed por­traits

8 years ago

Al­ler­gan vet Doug In­gram takes the helm of a storm-tossed Sarep­ta

8 years ago

Scoop: Mar­tin Shkre­li bats back a coup at Tur­ing, new board con­sid­ers a sale of as­sets

8 years ago

Af­ter months of taunts and tantrums, Mar­tin Shkre­li's fraud tri­al gets un­der­way

8 years ago

The End­points 100 CEO Sur­vey: Ex­ecs of­fer a big thumbs up for Got­tlieb and some sug­ges­tions for mak­ing the FDA a bet­ter agency

8 years ago
R&D

As­traZeneca and Glax­o­SmithK­line come to a peace­ful set­tle­ment of their tug of war over Luke Miels

8 years ago
First page Previous page 93949596979899 Next page Last page
A service from the Financial Times